DeLLphi-305: Tarlatamab + Durvalumab Improves Survival in SCLC | ESMO 2026
More on lung and thoracic cancers
- NEW for ESMO26The OncoAlert Network
NEW for ESMO26: Podium2Screen Dr. Alexander Drilon from Memorial Sloan Kettering Cancer Center
Trial update. ESMO 2026.
- Can a blood test detect cancer earlier—but still fail to demonstrate clinical utility?
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Publication pick. NEJM. October 9, 2026.
- Could immune biology finally tell us which patients with extensive-stage SCLC are most likely to benefit from TIGIT-based therapy?
SKYSCRAPER-02C A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China
Publication pick. Journal if Thoracic Oncology. October 7, 2026.
- Does adding immunotherapy to SBRT actually improve outcomes in early-stage, medically inoperable NSCLC or simply add toxicity?
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914)
Publication pick. The Lancet. October 5, 2026.
- HARMONi-6Dr. Hidehito Horinouchi
HARMONi-6, explained in Japanese
Dr. Hidehito Horinouchi. Expert pick. ESMO 2025.
- Lung cancerDr. Biagio Ricciuti
Lung cancer: the picks from Berlin
Dr. Biagio Ricciuti. Expert pick. ESMO 2025.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.